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Andrew H Ford1,2,3, Leon Flicker1,4,5, Kieran McCaul1, Frank van Bockxmeer6,7, Sarah Hegarty1,2, Varsha Hirani1,2,
Stephen Fenner3 and Osvaldo P Almeida1,2,3*
Correction
Following the publication of our article [1], we noticed
an error regarding the dosage of vitamin B12. In the
manuscript, we reported that the daily dosage of vitamin
B12 would be 0.4 mg, when in fact the dosage of vita-
min B12 used in the B-VITAGE trial is 0.5 mg per day.
In the abstract:
The B-VITAGE trial is a 12-month randomized, dou-
ble-blind, placebo-controlled trial of daily citalopram (20
to 40 mg) plus B12(0.4 mg), B6 (25 mg) and folic acid (2
mg) or citalopram (20 to 40 mg) plus placebo for the
treatment of depression in later life.
Should read
The B-VITAGE trial is a 12-month randomized, dou-
ble-blind, placebo-controlled trial of daily citalopram (20
to 40 mg) plus B12(0.5 mg), B6 (25 mg) and folic acid (2
mg) or citalopram (20 to 40 mg) plus placebo for the
treatment of depression in later life.
In the “Intervention and Blinding” section:
Eligible participants will be randomly allocated to
treatment with citalopram plus 400 μg vitamin B12, 2
mg folic acid and 25 mg B6 or citalopram plus placebo.
Should read
Eligible participants will be randomly allocated to
treatment with citalopram plus 500 μg vitamin B12, 2
mg folic acid and 25 mg B6 or citalopram plus placebo.
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